High Speed ICG Ranibizumab AMD (08-EI-0103)

用雷珠单抗治疗的AMD中脉络膜新生血管的ICG分析表明，尽管渗出减少，但对实际脉络膜新生血管的影响极小。初步的一年结果显示，脉络膜新生血管膜的平均大小只有5%的变化，与吲哚菁绿色血管造影分级。 最小强度投影OCT是一种识别和显示内界膜和视网膜色素上皮之间最小光强的新算法。 该软件最初开发用于提供正面眼底图像，其中流体呈现为暗区。 令人惊讶的是，还注意到明亮区域，这些区域似乎对应于覆盖脉络膜新生血管的外视网膜区域。 1年的结果显示，minIpOCT观察到的外部视网膜变化面积平均增加6%。 这些数据表明，雷珠单抗形式的抗VEGF治疗对罪犯脉络膜新生血管本身具有最小的作用。 这为评估其他潜在的新生血管性年龄相关性黄斑变性治疗提供了有用的数据。 根据所有参与者的共同终止日期，本研究于2014财年结束。

ICG analysis of choroidal neovascularization in AMD treated with ranibizumab suggests that there is minimal effect on the actual choroidal neovascularization despite reduction in exudation. The preliminary one year results showed only a 5% change in the mean size of the choroidal neovascular membrane as graded with indocyanine green angiography. Minimal intensity projection OCT is a novel algorithm that identifies and displays the minimum optical intensity found between the internal limiting membrane and retinal pigment epithelium. The software was initially developed to provide an en face fundus image where fluid presented as dark regions. Surprisingly, bright areas were also noted and these seem to correspond to the outer retinal area overlying the choroidal neovascularization. The one year results showed a mean 6% increase in the area of outer retinal change noted with minIpOCT. These data suggest that anti-VEGF treatment in the form of ranibizumab has mininal effect on the culprit choroidal neovascularization itself. This provides useful data to assess other potential neovascular age related macular degeneration treatments. The study was closed in fiscal year 2014, based on a common termination date for all participants.